checkmate 67t and the potential of subcutaneous nivolumab administration
Published 7 months ago • 141 plays • Length 5:33Download video MP4
Download video MP3
Similar videos
-
10:22
checkmate 67t: subcutaneous nivolumab for advanced or metastatic clear cell rcc
-
1:59
checkmate 67t: subcutaneous versus intravenous nivolumab in ccrcc
-
7:05
checkmate 67t offers a look at a different treatment route of administration
-
10:12
session 5: subcutaneous vs intravenous nivolumab in metastatic rcc | checkmate67t & litespark-005
-
3:35
checkmate-9er discussion: depth of response with first-line cabozantinib/nivolumab
-
3:59
checkmate 067 - combined nivolumab and ipilimumab
-
3:31
cabozantinib–nivolumab and ipilimumab combinations show potential for gu cancers | andrea apolo
-
1:58
dr. plimack on significance of checkmate-025 trial in rcc
-
5:10
checkmate 214: patterns of progression with nivolumab plus ipilimumab versus sunitinib for rcc
-
3:23
nivolumab improves overall survival for advanced kidney cancer
-
0:39
dr. lopes on the fda approval of nivolumab/ipilimumab in nsclc
-
1:33
dr. mcdermott on single-agent nivolumab in rcc
-
4:35
checkmate 8y8 trial in progress: what are the implications for this doublet?
-
1:35
checkmate-9er shows efficacy of nivolumab/cabozantinib combo in rcc
-
6:31
checkmate 649 biomarker analyses of nivo ipi vs chemo for patients with gc/gejc/eac
-
6:01
metastatic rcc: using frontline ipilimumab/nivolumab
-
0:41
dr. toni choueiri on cabozantinib and nivolumab combination in kidney cancer
-
5:58
checkmate 9er update confirms benefits of nivolumab–cabozantinib in rcc | cristina suárez
-
4:50
ipilimumab/nivolumab in first-line mrcc